ReviewHemaSphere2026
Inherited microcytic anemias due to disorders of iron and heme metabolism: An updated clinical review.
Review in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microcytic anemia is among the most common hematological abnormalities in clinical practice and is usually attributable to iron deficiency, thalassemia traits, or anemia of inflammation. A small but clinically important subset of patients, however, has inherited disorders of iron metabolism or heme synthesis presenting with persistent, unexplained, familial, or iron-refractory microcytosis. Over the past decade, advances in the understanding of the hepcidin-ferroportin axis, erythroid iron regulation, standardized hepcidin assays, and next-generation sequencing have substantially refined diagnosis, while expert guidance for iron-refractory iron deficiency anemia (IRIDA) has refined management, and hepcidin-targeted therapies in early development signal a shift towards mechanism-based treatment, though their role in IRIDA remains investigational. This review provides an updated, clinically oriented framework for inherited microcytic anemias caused by defects in systemic iron homeostasis, cellular iron transport, mitochondrial iron utilization, and heme biosynthesis. We propose a contemporary diagnostic algorithm integrating clinical features, iron biomarkers, hepcidin assessment, and molecular testing, and review current and emerging therapeutic strategies. Early recognition enables accurate diagnosis, avoids inappropriate investigations and treatment, facilitates genetic counselling, and helps prevent irreversible organ damage, particularly in iron-overload disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.